John P. Hamill
Senior VP, CFO, Principal Accounting Officer & SecretaryMr. John P. Hamill, CPA, serves as Chief Financial Officer and Secretary at Aprea Therapeutics, Inc. since January 30, 2023 and serves as its Principal Accounting Officer & Senior Vice President since January 30, 2023. He serves as Senior Vice President and Chief Financial Officer at Aprea Therapeutics AB since 2023. He was Senior Vice President and Chief Financial Officer at Windtree Therapeutics, Inc. since June 2020 until January 27, 2023 and also served as its Treasurer and Corporate Secretary until January 27, 2023. He served as a Vice President of Finance at Trevena, Inc. from August 2018 to August 2019 and served as its Interim Chief Financial Officer since June 2018 until August 2018. He has vast finance and accounting experience. He served as Interim Chief Financial Officer at Cellectar Biosciences, Inc. since September 5, 2017 until March 2018. Mr. Hamill served as the Chief Financial Officer of NephroGenex, Inc. from January 2014 to March 2016 and served as its Chief Executive Officer from April 13, 2016 to May 2017 and also served as its Secretary and Treasurer. Mr. Hamill served as Co-President of Savient Pharmaceuticals, Inc. since June 20, 2013 until January 2014. Mr. Hamill served as the Chief Financial Officer of Savient Pharmaceuticals, Inc. since September 24, 2012 until January 2014 and served as its Treasurer since September 24, 2012. He served as Senior Vice President of Savient Pharmaceuticals, Inc. since September 24, 2012. Mr. Hamill served as Chief Financial Officer of inVentiv Health Clinical, Inc. (formerly SFBC International Inc) since August 28, 2006 and also served as its Treasurer and Secretary since August 2006. From June 2017 through July 2018, Mr. Hamill maintained a consulting practice offering chief financial officer services such as, amongst other things, raising capital and budgeting. He served as an Executive Vice President of inVentiv Health Clinical, Inc. since September 2006 and also served as its Principal Accounting Officer. Mr. Hamill was Employed at PharmaNet Development Group, Inc. From 2001 to 2009 and served as its Executive Vice President and Chief Financial Officer from 2006 to 2009. He served as Senior Vice President of inVentiv Health Clinical, Inc.'s subsidiary, PharmaNet Inc., since January 2006 until 2009. He served as Vice President and Chief Financial Officer of PharmaNet Inc., from September 2004 to January 2006 and also served as its Vice President of Finance from January 2004 to September 2004 and Corporate Controller since July 2001. Prior to PharmaNet Inc., Mr. Hamill served as the Vice President, Interim Chief Financial Officer and Corporate Controller of Omnicare Clinical Research Inc., from 1998 to 2001. He also served as Manager of Finance and Administration of Rhone-Poulenc from 1997 to 1998 and also served as Manager of Corporate Financial Reporting of Freedom Chemical Company from 1994 to 1997. He held financial management positions at International Paper and Johnson & Johnson. He is a Certified Public Accountant and is a Member of Pennsylvania and American Institutes of Certified Public Accountants. Mr. Hamill holds a Bachelor of Science in Accounting/Business and Computer Science from DeSales University. He is a member of the Pennsylvania Institute of Certified Public Accountants and the American Institute of Certified Public Accountants.
Positions
- Company NameAprea Therapeutics, Inc.Stock CodeAPREPositionSenior VP, CFO, Principal Accounting Officer & SecretaryColleagues
- OGOren GiladCo-Founder, CEO, President & Director
- RPRichard PetersIndependent Chairperson of the Board
- LBLars B. AbrahmsenSenior VP & Chief Scientific Officer
- BWBrian WileySenior Vice President of Corporate Development & Strategy
- MAMichel AfarganHead of Pharmacology Development
- MJMichael J. GrissingerIndependent Director
- JBJohn B. HennemanIndependent Director
- RPRifat PamukcuIndependent Director
